trial · primary record
Ficerafusp alfa
Metastatic Head and Neck Squamous Cell Carcinoma
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 650 |
| Primary completion | 2029-07 |
| Primary endpoint | Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation. |
| Registry ID | NCT06788990 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:35:11.607Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06788990
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.